What this is
- This research investigates the presence of in individuals with long COVID.
- The study analyzes blood samples from 99 long COVID patients and 29 healthy controls.
- It identifies various inflammatory molecules trapped in these microclots, which may contribute to persistent symptoms.
Essence
- Long COVID patients exhibit in circulation, containing inflammatory molecules that may hinder normal clot breakdown and contribute to ongoing symptoms.
Key takeaways
- Long COVID patients demonstrate a significant load of that resist breakdown, potentially exacerbating symptoms.
- Proteomics analysis reveals various inflammatory molecules, including α(2)-antiplasmin and von Willebrand factor, entrapped in these microclots.
- Current pathology tests fail to detect these microclots, leading to confusion among patients and clinicians regarding the underlying causes of long COVID symptoms.
Caveats
- The study's findings are based on a specific cohort, which may limit the generalizability of the results.
- Further research is needed to develop biomarkers capable of detecting these microclots in clinical settings.
Definitions
- fibrin amyloid microclots: Microscopic clots formed from fibrin and amyloid proteins that resist normal breakdown and may entrap inflammatory molecules.
AI simplified
Introduction
Post-acute sequelae of COVID-19 (PASC), now commonly referred to as long COVID, has quickly become a major global health and economic burden [1 –4]. SARS-CoV-2 typically makes use of the cell surface receptor angiotensin-converting enzyme 2 (ACE2), to enter target cells. ACE2 receptors are expressed on the surface of lung epithelial cells, enterocytes of the small intestine and are also present in arterial and venous endothelial cells as well as arterial smooth muscle cells of multiple organs [5]. Viral replication leads to cellular damage and the release of pro-inflammatory alarmins due to cell injury and death [6]. The complement system may be activated by locally formed immune complexes which would inevitably boost the inflammatory response [7]. The activation of the complement cascade directly leads to endothelial damage and C3a and C5a formation recruits leucocytes that are responsible for a substantial local release of pro-inflammatory cytokines such as interleukin IL-1, IL-6, IL-8 and interferon-γ [8]. Fabio Ciceri and co-authors suggested the use of the term MicroCLOTS (microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome) [9]. They used this term as an atypical acute respiratory distress syndrome because of lung damage, primarily explained by dramatic alveolar endothelial damage leading to a progressive endothelial pulmonary syndrome with microvascular thrombosis [9]. In the acute phase of COVID-19, patients present with multi-organ symptoms [10] and this phase is characterized by acute clinical pathologies, including various coagulopathies that may be accompanied by hypercoagulation and platelet hyperactivation [11 –17]. If these coagulopathies are not adequately treated during the acute phase of the disease, possible tissue hypoxia and impaired oxygen exchange may linger for months. The resulting underlying pathologies can directly perpetuate lingering long COVID symptoms that include fatigue or muscle weakness, dyspnoea, cognitive impairment, insomnia, and anxiety or depression.
We recently provided evidence, based on a relatively small cohort of patients, that individuals with long COVID present with a significant fibrin amyloid microclot load in their circulation and that these persistent microclots are resistant to fibrinolysis [1]. Microclots as described further in this paper, will refer to microscopic (fibrin-amyloid-containing) clots present in the plasma of recruited individuals and not MicroCLOTS, the syndrome as suggested by Ciceri and co-authors [9]. In our previously mentioned work, we used techniques including proteomics and fluorescence microscopy to study plasma samples from healthy individuals, individuals with type 2 diabetes mellitus (T2DM), those with acute COVID-19, and those with long COVID symptoms. Plasma samples from long COVID patients still contained large amounts of anomalous (amyloid) microclots that are resistant to fibrinolysis (compared to the plasma from controls and T2DM), even after trypsinisation. We could solubilize the microclots only after a second trypsinization step. The most noteworthy inflammatory molecules that were trapped in the solubilized microclots present in plasma of long COVID patients, versus the equivalent volume of fully digested plasma fluid of control samples, were α(2)-antiplasmin (α2AP), various fibrinogen chains, von Willebrand factor (VWF), and Serum Amyloid A (SAA). In addition to the natural resistance of protein amyloid structures to proteolysis [18] these trapped molecules could indeed result in fibrinolytic-resistant pellet microclots [1, 19].
We have now embarked on a considerably more extensive analysis of these microclot contents. We used proteomics to study blood samples from 99 long COVID patients and 29 healthy controls. There is increasing evidence that autoantibodies may be involved in the lingering symptoms of these patients [20 –22]. Thus, in addition to molecules of interest that are related to clotting, we also focused on the presence of antibodies or autoantibodies that might be associated with or trapped inside the fibrinolysis-resistant microclots.
Materials and methods
Ethical clearance
Ethical clearance for the study was obtained from the Health Research Ethics Committee (HREC) of Stellenbosch University (South Africa) (references: B21/03/001_COVID-19, project ID: 21,911 (long COVID registry) and N19/03/043, project ID 9521 with yearly re-approval). Participants were either recruited via the long COVID registry or identified from our clinical collaborators' practice. The experimental objectives, risks, and details were explained to volunteers and informed consent were obtained prior to blood collection. Strict compliance to ethical guidelines and principles Declaration of Helsinki, South African Guidelines for Good Clinical Practice, and Medical Research Council Ethical Guidelines for Research were kept for the duration of the study and for all research protocols.
Sample demographics and considerations
Blood was collected from 29 volunteers (9 males; 20 females; median age 52 [range 41–57]) to serve as controls. Control patients did not smoke or suffer from coagulopathies, were not pregnant and only 1 volunteer suffered from cardiovascular disease. Those suffering from hypertension or hyperlipidaemia, were well controlled on treatment and none of our controls took anticoagulation medication. Initially, we included 99 long COVID patients in the study (30 males, 69 females.) Liquid chromatography and mass spectrometry were performed on all of the samples and data collected. 66 of the long COVID samples were found to be "high responders" and 24 "low responders" (please refer to the mass spectrometry data analysis section for an in-depth explanation of the classification.) Mass spectrometry data analysis was only carried out on the high responder long COVID samples. The median age of high responders was 51 [40 –60] (21 males; 45 females) and the median age of low responders 45 [31 –58] (5 males; 19 females.) Healthy participants, patients or their attending physicians completed a questionnaire, either as part of the long COVID registry or when they visited their attending clinician. The questionnaire contained information regarding their age, gender, pre-existing comorbid conditions, chronic medication, information regarding the onset, diagnosis, and severity of their acute COVID-19 illness, self-reported long COVID symptoms, as well as their COVID-19 vaccination history (where available).
Blood sample collection
Either a qualified phlebotomist or medical practitioner drew blood samples. Blood samples were collected in 4.5 mL sodium citrate (3.2%), 4 ml lithium heparin (75 USP units) and 5 ml rapid serum (thrombin-based clot activator) tubes (BD Vacutainer®, 369714)), via venepuncture, adhering to the standard sterile protocol. On the day of blood collection, natriuretic peptide tests measuring levels of BNP or NT-proBNP, serum ferritin and Interleukin-6 (IL-6) levels were analysed by a pathology lab. NT-proBNP were analysed to determine that our cohort did not have underlying heart failure that might falsely suggest coagulopathies are due to long COVID. If NT-proBNP levels were not available, the attending clinician ensured that the patients had normal echocardiograms. Whole blood (WB) was centrifuged at 3000xg for 15 min at room temperature and the supernatant platelet poor plasma (PPP) samples were collected in 1.5 mL Eppendorf tubes and stored at – 80 °C.
Double trypsin digestion protocol to solubilize microclots in PPP
Stored PPP was used to determine protein concentration using nanodrop technology where a 20 × dilution was made with 10 mM ammonium bicarbonate and protein concentration determined using a nanodrop spectrophotometer (Thermo Fischer) and measuring the absorbance at 280 nm. The samples were then standardised to the lowest protein concentration and 50 µg total protein removed for digestion (25 µL). For the first trypsin digestion step, 50 µg of protein per sample was placed in a tube and 25 µL ammonium bicarbonate and 1 µg of trypsin was added to a final volume of 50 µL. The samples were incubated over night at 37 °C.
For the second trypsin digestion step, the samples were centrifuged the next day at 16,000g for 10 min (volume in each sample were still 50 µL). Next, 42 µL of supernatant were removed carefully to not do not disturb the microclots at bottom of tube. To the remaining 8 µL, 10 µL of 250 mM Triethyamonium bicarbonate (TEAB) (ThermoFisher) containing 5 mM tris carboxyethyl phosphine (TCEP) (Sigma), was added. The samples were vortexed for 5 s followed by incubation of 10 min at 90 °C. Samples where then incubated for a further 50 min at 60 °C, followed by a cooling-down step. Cysteine residues were blocked using 10 mM (final concentration) methyl methanethiosulfonate (MMTS) (we added 1 µl into each sample). Samples were left at room temp for 30 min. Thereafter, 20 µL of 50% (Sigma) methanol was added and samples were vortexed for 5 s (to denature last intact proteins that might remain). Now 10 µL of trypsin solution in 100 mM TEAB (containing 1 µg of trypsin) (Thermo) was added to each sample followed by incubation for 18 h at 37 °C. Samples were then acidified with 5 µL trifluoroacetic acid (TFA) (Sigma) of which the final concentration of 0.5% was used to precipitate trypsin. Samples where centrifuged at 16,000g to pellet the trypsin precipitate and the supernatant removed and placed into HPLC inserts. Samples were allowed to evaporate to dryness under vacuum (roto-evaporator) followed by resuspending in 20µL loading buffer consisting of 2% acetonitrile (Burdick and Jackson) in deionized water containing 0.1% Formic acid (Sigma) spiked with Biognosys 11 indexed retention times standards (Biognosys.) The dissolved samples were loaded directly in the autosampler set to 4C.
Liquid chromatography of digested microclots
Liquid chromatography was performed on a Thermo Scientific Ultimate 3000 RSLC [23, 24] equipped with a 20 mm × 100 µm C18 trap column (Thermo Scientific) and a CSH 25cmx75µm 1.7 µm particle size C18 column (Waters) analytical column. The solvent system employed was loading: 2% acetonitrile:water; 0.1% FA; Solvent A: water; 0.1% FA and Solvent B: 100% acetonitrile, 0.15% FA. Methods were previously described in [1]. Separation was effected using a linear gradient from 2 B to 30% B over 65 min followed by 30 B to 45% B from 65 to 80 min. The sample was loaded onto a trap column at 2 µL/min before switching to the analytical column at three minutes with a flow rate of 300 nL/min. Chromatography was performed at 45 °C and the outflow delivered to the mass spectrometer through a stainless-steel nano-bore emitter.
Mass spectrometry of digested microclots
Mass spectrometry was performed using a Thermo Scientific Fusion mass spectrometer equipped with a Nanospray Flex ionization source. Data was collected in positive ion mode with spray voltage set to 1.8 kV and ion transfer capillary set to 275 °C. The mass spectrometer auto-calibration was activated using polysiloxane ions at m/z = 445.12003. MS1 scans were performed using the orbitrap detector set at 120,000 resolution over the scan range 375–1500 with AGC target at 2 E4 and maximum injection time of 50 ms. Data were acquired in profile mode. MS2 acquisitions were performed using monoisotopic precursor selection for ion with charges + 2 to + 7 with error tolerance set to ± 10 ppm. Precursor ions were excluded from fragmentation once for a period of 60 s. Precursor ions were selected for fragmentation in HCD mode using the quadrupole mass analyser with HCD energy set to 30%. Quadrupole isolation was set at m/z = 1.2. Fragment ions were detected in the Orbitrap mass analyser set to 30,000 resolution. The AGC target was set to 5E4 and the maximum injection time to 100 ms. The data was acquired in centroid mode. Samples were randomised by using a randomization schedule. Technical replicates are not feasible in an experiment with a large sample size such as this.
Mass spectrometry data analysis
The raw files generated by the mass spectrometer were imported into SearchGUI [25] and processed using the MsGF + algorithm. Database interrogation was performed against the 2019-nCOVpFASTA database [26]. Semi-tryptic cleavage with 2 missed cleavages was allowed for. Precursor mass tolerance was set to 10 ppm and fragment mass tolerance set to 0.02 Da. Deamidation (NQ), oxidation (M) and Phosho-ST were allowed as dynamic modifications and methylthio of C as a fixed modification. Data was imported into Skyline and the extracted ion chromatograms of positively identified peptides summated as indication of relative protein abundance. Spectral data were evaluated in Skyline and the proteomics sample was divided into high and low responders. Samples where 90% of all the protein intensity level read outs (or the area under the peak) were above the 3rd quartile when compared to the protein levels observed in our other samples, were classified as "high responders". If 90% of all the protein intensity level read outs were below the 1st quartile when compared to the proteins in other samples, they were classified as "low responders." For example, if there were 100 proteins identified but 90 of those proteins had concentrations/responses that were below the 1st quartile compared to the other samples in the sample set, the patient was classified as a low responder. Low responders were excluded from further analysis. We ensured that it was not attributable to instrument performance and batch effects were also excluded. The search results were imported into Scaffold Q + for further validation (www.proteomesoftware.com↗) and statistical testing. The (FDR) false discovery rate was set to 1%. Normalization was selected in Scaffold Q + with a weighted spectra quantitation method and missing values were processed by the algorithm contained within the software. A Fischer's exact test (F-test) was performed on the dataset and Benjaminin-Hochberg multiple testing correction applied. This resulted in a p-value of < 0.012. For immunoglobulin specific searches the FASTA files were obtained from uniprot (www.uniprot.org↗) by searching the database for human immunoglobulins and downloading the returned protein sequences. Protein parsimony for immunoglobulin searches was handled by peptide and Protein Prohpet algorithms within Scaffold. The immunoglobulins listed later in the paper (as shown in Table 3 and Table 4,) were cross referenced on THE INTERNATIONAL IMMUNOGENETICS INFORMATION SYSTEM®'s IMGT/LIGM-DB database (nucleotide sequences of IG and TR from 360 species.) The citable accession numbers of the immunoglobulins were used to determine the EMBLi reference number to search for the particular immunoglobulin on the database: https://www.imgt.org/ligmdb/↗ Our proteomics data will be deposited in an international repository such as PRIDE (EBI) for public access.
PPP and the detection of amyloid fibrin(ogen) protein and anomalous micro-clotting
Fluorescence microscopy of microclot formation in PPP was performed on some of our samples as described in our previous papers [17]. PPP were exposed to the fluorescent amyloid dye, Thioflavin T (ThT) (final concentration: 0.005 mM) (Sigma-Aldrich, St. Louis, MO, USA) for 30 min (protected from light) at room temperature [18, 27 –30]. After incubation, 3 µL stained PPP was placed on a glass slide and covered with a coverslip. The excitation wavelength band for ThT was set at 450 to 488 nm and the emission at 499 to 529 nm and processed samples were viewed using a Zeiss Axio Observer 7 fluorescent microscope with a Plan-Apochromat 63x/1.4 Oil DIC M27 objective (Carl Zeiss Microscopy, Munich, Germany).
Platelet pathology / evaluation
Haematocrit samples of a few of our patients in the cohort were exposed to the two fluorescent markers, CD62P (PE-conjugated) (platelet surface P-selectin) (IM1759U, Beckman Coulter, Brea, CA, USA) and PAC-1 (FITC-conjugated) (340507, BD Biosciences, San Jose, CA, USA) (17). CD62P is a marker for P-selectin that is either found on the membrane of platelets or inside them. PAC-1 identifies platelets through marking the glycoprotein IIb/IIIa (gpIIb/IIIa) on the platelet membrane. To study platelet pathology, 4 µL CD62P and 4 µL PAC-1 was added to 20 µL haematocrit, followed by incubation for 30 min and protected from light at room temperature. The excitation wavelength band for PAC-1 was set at 450 to 488 nm and the emission at 499 to 529 nm and for the CD62P marker it was 540 to 570 nm and the emission 577 to 607 nm [17]. Samples were viewed using a Zeiss Axio Observer 7 fluorescent microscope with a Plan-Apochromat 63x/1.4 Oil DIC M27 objective (Carl Zeiss Microscopy, Munich, Germany).
Statistics
Statistical analysis was done using Graphpad Prism 8 (version 8.4.3). All data were subjected to Shapiro-Wilks normality tests. An unpaired T-test was performed on parametric data with the data expressed as mean ± standard deviation, whereas the Mann–Whitney U test was used on unpaired non-parametric data and the data expressed as median [Q1–Q3] (all two-tailed).
Results
Individuals suffering from long COVID in South Africa, were invited to fill in an online South African long COVID registry and they could, in addition, opt to be contacted to provide a blood sample (ethics number for registry: B21/03/001_COVID-19, project ID: 21911). Individuals that served as controls, were also recruited for a blood sample and filled in consent forms as per ethics number N19/03/043, project ID 9521.
Stripe plots comparing the unique peptide counts of VWF, plasma Kallikrein and PF4 between patients suffering from hypertension and hyperlipidaemia in our long COVID and control population. This demonstrates that there is no correlation between patients suffering from hypertension or hyperlipidaemia and that it doesn't serve to differentiate between the groups. (Created with BioRender.com.)
![Fluorescence microscopy showing platelets and microclots in individuals with long COVID and control samples. The first 2 columns show platelets in the haematocrit and the last column shows microclots in PPP. PPP were exposed to ThT, a fluorescent amyloid dye (final concentration: 0.005 mM) (Sigma-Aldrich, St. Louis, MO, USA) for 30 min at room temperature and protected from light. The same scoring system can be utilized to evaluate and interpret the fibrinaloid microclot load severity in PPP as published in our previous work []. We are aware that this isn't a perfect system to aid as a quantitative score for qualitative data. Stage 1 would represent a minimal fibrinaloid microclot load as seen in healthy/control PPP, whereas Stage 4 represents a severe fibrinaloid microclot load. The fluorescent micrographs of representative samples of our long COVID cohort and control patients of haematocrit samples are stained with PAC-1 (green fluorescence) and CD62P-PE (purple fluorescence). The white areas represent areas where the two markers overlap, and the images were taken at 63 × magnification. The scoring system as described by Laubscher and Lourens et al. can be used to evaluate platelet activation and clumping in these fluorescence micrographs. In Stage 1 platelets are minimally activated and are seen as small and round with few pseudopodia (representative of healthy/control platelets). Severe platelet activation, or Stage 4 activation, is characterized by large, egg-shaped morphology with aggregations and is indicative of hyperactivated platelets. Similarly, platelet clumping can also be assessed with no clumping seen in healthy/control samples, which is classified as Stage 1 and severe clumping of platelets seen in Stage 4. Therefore, in our long COVID cohort, the fibrinaloid microclot load severity would fit with a severity of stage 2 to 3, and in some instances even a stage 4 (severe microclot load). Mild to moderate platelet activation (stage 2 to 3), as well as clumping are seen in micrographs,,and [17] D E G H](https://europepmc.org/articles/PMC9491257/bin/12933_2022_1623_Fig2_HTML.jpg "Click to view full size")
Fluorescence microscopy showing platelets and microclots in individuals with long COVID and control samples. The first 2 columns show platelets in the haematocrit and the last column shows microclots in PPP. PPP were exposed to ThT, a fluorescent amyloid dye (final concentration: 0.005 mM) (Sigma-Aldrich, St. Louis, MO, USA) for 30 min at room temperature and protected from light. The same scoring system can be utilized to evaluate and interpret the fibrinaloid microclot load severity in PPP as published in our previous work []. We are aware that this isn't a perfect system to aid as a quantitative score for qualitative data. Stage 1 would represent a minimal fibrinaloid microclot load as seen in healthy/control PPP, whereas Stage 4 represents a severe fibrinaloid microclot load. The fluorescent micrographs of representative samples of our long COVID cohort and control patients of haematocrit samples are stained with PAC-1 (green fluorescence) and CD62P-PE (purple fluorescence). The white areas represent areas where the two markers overlap, and the images were taken at 63 × magnification. The scoring system as described by Laubscher and Lourens et al. can be used to evaluate platelet activation and clumping in these fluorescence micrographs. In Stage 1 platelets are minimally activated and are seen as small and round with few pseudopodia (representative of healthy/control platelets). Severe platelet activation, or Stage 4 activation, is characterized by large, egg-shaped morphology with aggregations and is indicative of hyperactivated platelets. Similarly, platelet clumping can also be assessed with no clumping seen in healthy/control samples, which is classified as Stage 1 and severe clumping of platelets seen in Stage 4. Therefore, in our long COVID cohort, the fibrinaloid microclot load severity would fit with a severity of stage 2 to 3, and in some instances even a stage 4 (severe microclot load). Mild to moderate platelet activation (stage 2 to 3), as well as clumping are seen in micrographs,,and [17] D E G H
| Demographics | |
|---|---|
| Median age of healthy individuals (n = 29) | 52 [41–57] |
| Median age of long COVID (high responders) (n = 66) | 51 [40–60] |
| Median age of long COVID (low responders) (n = 24) | 45 [31–58] |
| Uniprot ID | Molecule | Uniprot description / function if available (as specified on Uniprot website or references in the column) | Fold change | p-Value |
|---|---|---|---|---|
| Molecules of interest involved in the coagulation system found to be INCREASED in the long COVID sample vs healthy sample | ||||
| P04275 | VWF_HUMAN / von Willebrand factor | Important in the maintenance of haemostasis.Also acts as a chaperone for coagulation factor VIII delivering it to the site of injury stabilizing its heterodimeric structure and protecting it from premature clearance from plasmaIt promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. | 2.6 | 9.4 × 10− 11 |
| P02775 | CXCL7_HUMAN / Platelet basic protein (LA-PFA4) | LA-PF4 stimulates DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan.It also stimulates the formation and secretion of plasminogen activator by human synovial cells | 3.5 | 3.5 × 10− 05 |
| P08697 | A2AP_HUMAN / α(2)-antiplasmin | Serine protease inhibitor., but it also inactivates matriptase-3/TMPRSS7 and chymotrypsinThe major targets of this inhibitor are plasmin and trypsin | 1.3 | 0.0098 (Marginally increased) |
| Molecules of interest involved in the coagulation system found to be REDUCED in the long COVID sample vs healthy sample | ||||
| P03952 | KLKB1_HUMAN / Plasma kallikrein | The enzyme cleaves Lys-Arg and Arg-Ser bonds.It also releases bradykinin from HMW kininogen and may also play a role in the renin-angiotensin system by converting prorenin into reninIt activates in a reciprocal reaction, factor XII after its binding to a negatively charged surface. | 4.4 | 4.2 × 10− 07 |
| Molecules of interest involved in cellular function found to be INCREASED in the long COVID sample vs healthy sample | ||||
| Q08380 | LG3BP_HUMAN / Galectin-3-binding protein | Promotes integrin-mediated cell adhesion.May stimulate host defence against viruses and tumour cells | 2.3 | 3.9 × 10− 07 |
| P07996 | TSP1_HUMAN /Thrombospondin-1 | . May play a role in dentinogenesis and/or maintenance of dentin and dental pulpAdhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. Binds heparinLigand for CD36 mediating antiangiogenic properties. Plays a role in ER stress response via its interaction with the activating transcription factor 6 alpha (ATF6) which produces adaptive ER stress response factors (by similarity.) | 2.4 | 5.1 × 10− 05 |
| P19652 | A1AG2_HUMAN / Alpha-1-acid glycoprotein 2 | Functions as transport protein in the blood stream. Binds various hydrophobic ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability.Appears to function in modulating the activity of the immune system during the acute-phase reaction | 2.8 | 2.5 × 10− 25 |
| P19827 | ITIH1_HUMAN / Inter-alpha-trypsin inhibitor heavy chain H1 | May act as a carrier of hyaluronan in serum or as a binding protein between hyaluronan and other matrix protein, including those on cell surfaces in tissues to regulate the localization. synthesis and degradation of hyaluronan which are essential to cells undergoing biological processes.Contains a potential peptide which could stimulate a broad spectrum of phagocytotic cells | 2.1 | 1.4 × 10− 17 |
| P19823 | ITIH2_HUMAN / Inter-alpha-trypsin inhibitor heavy chain H2 | May act as a carrier of hyaluronan in serum or as a binding protein between hyaluronan and other matrix protein, including those on cell surfaces in tissues to regulate the localization, synthesis and degradation of hyaluronan which are essential to cells undergoing biological processes | 1.5 | 8.7 × 10− 09 |
| Molecules of interest involved in cellular function found to be REDUCED in the long COVID vs healthy sample | ||||
| Q8TDL5 | LPLC1_HUMAN / Long palate, lung and nasal epithelium carcinoma-associated protein 1 | May play a role in innate immunity in mouth, nose and lungs. Binds bacterial lipopolysaccharide (LPS) and modulates the cellular responses to LPS | 4.7 | 0.0009 |
| P02788 | TRFL_HUMAN / Lactotransferrin | in association with the binding of an anionTransferrins are iron binding transport proteins which can bind two Feions+3 | 2.3 | 0.006 |
| Q15848 | ADIPO_HUMAN / Adiponectin | . Stimulates AMPK phosphorylation and activation in the liver and the skeletal muscle, enhancing glucose utilization and fatty-acid combustion. Antagonizes TNF-alpha by negatively regulating its expression in various tissues such as liver and macrophages and also by counteracting its effects, Inhibits endothelial NF-kappa-B signalling through a cAMP-dependent pathway. May play a role in cell growth, angiogenesis and tissue remodelling by binding and sequestering various growth factors with distinct binding affinities, depending on the type of complex, LMW, MMW or HMWImportant adipokine involved in the control of fat metabolism and insulin sensitivity, with direct anti-diabetic, anti-atherogenic and anti-inflammatory activities | 4.9 | 5.1 × 10− 05 |
| P02763 | A1AG1_HUMAN / Alpha-1-acid glycoprotein 1 | Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body.Appears to function in modulating the activity of the immune system during the acute-phase reaction | 5.2 | 5.0 × 10− 28 |
| Molecules of interest involved in lipid metabolism found to be INCREASED in the long COVID sample vs healthy sample | ||||
| P02655 | APOC2_HUMAN / Apolipoprotein C-II | Component of chylomicrons, (VLDL) very-low-density lipoproteins, low-density lipoproteins (LDL) and high-density lipoproteins (HDL) in plasma. Plays an important role in lipoprotein metabolism as an activator of lipoprotein lipase. Both proapolipoprotein C-II and apolipoprotein C-II can activate lipoprotein lipase. Present in normolipidemic individuals, it is mainly distributed in the HDL, whereas in hypertriglyceridemic individuals, predominantly found in the VLDL and LDL | 1.7 | 3.1 × 10− 06 |
| Molecules of interest involved in lipid metabolism found to be REDUCED in the long COVID sample vs healthy sample | ||||
| P02652 | APOA2_HUMAN / Apolipoprotein A | May stabilize HDL (high density lipoprotein) structure by its association with lipids and affect the HDL metabolism | 5.2 | 1.4 × 10− 14 |
| Immunoglobulin molecules (or fragments thereof) that were found to be INCREASED in the long COVID (high responder) sample vs the healthy sample | |||
|---|---|---|---|
| Uniprot ID | Molecule | Fold change | p-Value |
| P01876 | Immunoglobulin alpha-1 chain C region (IGHA1_HUMAN) | 1.5 | 1.2 × 10− 05 |
| A0A0C4DH32 | Immunoglobulin heavy chain V-III region GAL (HV320_HUMAN) | 1.6 | 5 × 10− 05 |
| P01602 | Immunoglobulin kappa chain V-I region HK102 (Fragment) (KV105_HUMAN) | 1.6 | 0.0003 |
| B9A064 | Immunoglobulin lambda-like polypeptide 5 (IGLL5_HUMAN) | 1.7 | 2.5 × 10− 11 |
| P01717 | Immunoglobulin lambda chain V-IV region Hil (LV403_HUMAN) | 1.8 | 1.7 × 10− 05 |
| P01763 | Immunoglobulin heavy chain V-III region WEA (HV348_HUMAN) | 1.9 | 0.005 |
| P01764 | Immunoglobulin heavy chain V-III region TUR (HV323_HUMAN) | 2.1 | 2.4 × 10− 05 |
| P04433 | Immunoglobulin kappa chain V-III region VG (Fragment) (KV311_HUMAN) | 2.4 | 1.5 × 10− 13 |
| P04207 | [] Immunoglobulin kappa chain V-III region CLL (B chronic lymphocytic leukaemia) (KV315_HUMAN) [32] [] CD5- B cell CLL cell population might produce pathologic IgM kappa rheumatoid factor autoantibodies [33] | 2.3 | 2.9 × 10− 08 |
| P01624 | Immunoglobulin kappa chain V-III region POM (plasma membrane)(KV315_HUMAN) rheumatoid factor | 2.3 | 0.01 |
| P04211 | Immunoglobulin lambda chain V region 4A (LV743_HUMAN) | 2.5 | 0.003 |
| P06331 | Immunoglobulin heavy chain V-II region ARH-77 (HV434_HUMAN) | 2.7 | 0.002 |
| P04430 | Immunoglobulin kappa chain V-I region BAN (KV116_HUMAN) | 2.8 | 2.7 × 10− 06 |
| P01762 | Immunoglobulin heavy chain V-III region TRO (HV311_HUMAN) | 2.8 | 1.0 × 10− 08 |
| P01619 | Immunoglobulin kappa chain V-III region NG9 (Fragment) (KV320_HUMAN) | 2.9 | 7.3 × 10− 05 |
| P01619 | Immunoglobulin kappa chain V-III region B6 (KV320_HUMAN) | 3.8 | 4.1 × 10− 06 |
| P80748 | Immunoglobulin lambda chain V-V region DEL (LV321_HUMAN) | 3.8 | 1.2 × 10− 08 |
| P01780 | Immunoglobulin heavy chain V-III region JON (HV307_HUMAN) | 4 | 0.002 |
| P01772 | Immunoglobulin heavy chain V-III region KOL (HV333_HUMAN) | 4.2 | 1.1 × 10− 05 |
| P01700 | Immunoglobulin lambda chain V-I region HA (LV147_HUMAN) | 4.6 | 2.3 × 10− 06 |
| P01767 | Immunoglobulin heavy chain V-III region BUT (HV353_HUMAN) | 5 | 1.8 × 10− 06 |
| P06312 | Immunoglobulin kappa chain V-IV region Len (KV401_HUMAN) | 5.6 | 9.9 × 10− 21 |
| P01700 | Immunoglobulin lambda chain V-I region WAH (LV147_HUMAN) | 14.8 | 2.4 × 10− 08 |
| P01593 | Immunoglobulin kappa chain V-I region Ni (KVD33_HUMAN) | 76 | 4.5 × 10− 42 |
| Citable accession number | Description | % |
|---|---|---|
| A0A5C2GW09_HUMAN | IG c1641_light_IGKV1-6_IGKJ4 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 27 |
| A0A5C2G4F7_HUMAN | IGL c3450_light_IGKV1-39_IGKJ1 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 24 |
| A0A7S5C1N4_HUMAN | IGH c2558_heavy_IGHV3-20_IGHD2-2_IGHJ2 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 22 |
| A0A5C2GTV9_HUMAN | IG c945_light_IGKV3-20_IGKJ1 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 21 |
| A0A5C2GZY9_HUMAN | IG c1248_light_IGLV1-44_IGLJ2 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 21 |
| A0A7S5EWW2_HUMAN | IGH c2567_heavy_IGHV1-24_IGHD5-18_IGHJ4 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 21 |
| A0A5C2G1R6_HUMAN | IGL c2854_light_IGLV1-40_IGLJ2 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 19 |
| A0A7S5BZI6_HUMAN | IGH c1057_heavy_IGHV3-11_IGHD4-23_IGHJ5 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 19 |
| A0A5C2FVE3_HUMAN | IGL c574_light_IGKV3-15_IGKJ5 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 17 |
| A0A5C2FZT4_HUMAN | IGL c1790_light_IGKV3-20_IGKJ3 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 17 |
| A0A5C2G099_HUMAN | IGL c977_light_IGKV3-20_IGKJ3 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 17 |
| A0A5C2G3Y0_HUMAN | IGL c3260_light_IGKV4-1_IGKJ1 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 17 |
| A0A5C2GC79_HUMAN | IGH + IGL c193_light_IGLV3-25_IGLJ3 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 17 |
| A0A5C2GJK9_HUMAN | IG c95_heavy_IGHV3-23_IGHD6-25_IGHJ4 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 17 |
| A0A5C2GVG8_HUMAN | IG c1565_light_IGKV2-28_IGKJ1 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 17 |
| A0A7S5EWD7_HUMAN | IGH c3300_heavy_IGHV3-33_IGHD5-18_IGHJ4 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 17 |
| A0A5C2GFW6_HUMAN | IG c686_heavy_IGHV3-20_IGHD6-25_IGHJ4 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 16 |
| A0A5C2G2C3_HUMAN | IGL c3319_light_IGKV1-8_IGKJ1 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 14 |
| A0A5C2G2K9_HUMAN | IGL c3511_light_IGKV1-9_IGKJ4 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 14 |
| A0A5C2GH36_HUMAN | IG c401_light_IGKV3-20_IGKJ4 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 14 |
| A0A5C2GYP0_HUMAN | IG c860_light_IGKV1D-33_IGKJ2 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 14 |
| A0A7S5C450_HUMAN | IGH c1450_heavy_IGHV3-49_IGHD4-4_IGHJ6 (Fragment) OS = Homo sapiens OX = 9606 PE = 2 SV = 1 | 14 |
Discussion
The current proteomics analysis of the content of the fibrin amyloid (plasma protein) microclots we found in our samples, identified increased or decreased levels of inflammatory molecules related to cellular function, coagulation, and lipid metabolism, as well as antibodies trapped inside these microclots. The fluorescent marker used was ThT (demarcated as the green signal in smears of the PPP as seen in Fig. 2). Small areas of protein misfolding will always be present in individuals, for example patients with type II diabetes mellitus, which has been implicated as a protein misfolding disease [36]. However, healthy individuals will also have minor plasma protein misfolding. Long COVID, as a disease, is still so new involves numerous organ systems and affects individuals with numerous comorbidities. In the current paper, we wish to shed more light on the levels of the molecules we found contained within these microclots, albeit increased or decreased and provide researchers and clinicians with a snapshot of the molecules present in patients suffering from long COVID. These molecules may contribute to the symptomatology of patients with long COVID, be involved in the pathophysiology thereof or potentially contribute to autoimmunity in these patients. Hopefully, as researchers piece together the disease pathophysiology, some of the molecules noted in this paper, will give some answers to unravel this very complex condition.
Individuals with previous reports of autoimmune diseases may also be more prone to develop long COVID. We also know that symptoms that develop during acute COVID infection can become chronic or persistent. We have recently discussed reasons for these persistent symptoms and suggested that it can particularly be ascribed to abnormal blood clotting, a dysfunction in clot lysis, and an entrapment of large numbers of inflammatory molecules inside of fibrinolytic-resistant microclots [35]. These microclots, together with large-scale platelet dysfunction and systemic endothelialitis, may possibly result in generalized cellular hypoxia [17, 35]. Cellular hypoxia, resulting from blockages of the capillaries by microclots might explain most of the persistent (albeit multifarious) symptoms that are noted in long COVID patients. When microclots block capillaries, the passage of red blood cells are limited, resulting in a reduced O2 and CO2 exchange [35].
We have previously noted that soluble fibrinogen in blood can clot into an anomalous 'amyloid' form of fibrin (fibrinaloids), that is comparatively resistant to fibrinolysis [35]. We have also shown that the reason for failed fibrinolysis, might be due to the presence of various molecules entrapped inside the clots, that might prevent clot breakdown [1, 11, 17]. This failed fibrinolysis phenomenon can explain why individuals with long COVID have extensive insoluble fibrinaloid microclots that can persist in circulation, albeit some are trapped in places that are not observed in a standard blood draw. An important consideration is that current pathology tests measure only the soluble inflammatory molecules in blood and standard pathology blood tests such as a full blood count or CRP (C-reactive protein) appear to be normal in these patients. However, if inflammatory molecules are entrapped inside (insoluble) microclots in circulation, the pathology tests will indeed show that the levels of inflammatory molecules are within normal pathology laboratory concentration ranges. From literature we know that IL-6, D-Dimer and fibrinogen levels are elevated in patients with COVID-19, indicating activation of coagulation pathways and a hypercoagulable state or thrombotic risk [48, 49]. The absence of biomarkers in standard pathology tests, result in a significant amount of confusion for patients and clinicians, as patients are extremely sick or even bed-ridden but with no regular identifiable reason for their disease. Biomarkers that are currently available cannot detect the molecules present in the microclots we identified and are therefore unable to confirm their presence or the mechanisms that drive their formation. Further studies are therefore necessary to develop a method or biomarker that would be able to detect and confirm these microclots in patients with long COVID and therefore the appropriate treatment thereof. Our current study, investigating the composition of these microclots, pave the way for future studies to detect their presence.
Our findings that microclots contain and entrap numerous inflammatory molecules, can immediately explain the reasons why traditional pathology tests such as a CRP or full blood count do not find many of the insoluble inflammatory molecules that are and may directly be involved in the disease presentation, pathophysiology and progression [1, 11, 17, 35].
Fibrin-amyloid microclots represent a novel and potentially important target for understanding their inflammatory content and also a target for the treatment of long COVID and related disorders [35]. If we look closely at the entrapped microclot molecules shown in Table 2 that might be directly relevant for cellular function, coagulation, and lipid metabolism we note both increased and decreased levels of molecules when we compare fold changes between healthy individuals and those with long COVID (see Table 2).
![A representation of our understanding of disease progression and pathophysiology from acute COVID-19 to long COVID.Depending on the severity of acute COVID-19 disease, dysregulation with increased levels of the following biomarkers have been found, namely P-selectin [], fibrinogen, D-dimer and VWF []. Abnormal clotting and hypercoagulability are seen early in acute COVID-19 disease with the development of thrombocytopaenia and a risk of bleeding as disease severity progresses. Therefore, the optimal time for intervention is early on in acute COVID-19 disease to address the presence of abnormal clotting.Progression to long COVID disease with patients presenting with debilitating symptoms such as "brainfog," dyspnoea, chest pain and chronic fatigue and the presence of microclots that may block capillaries with limited passage of red blood cells resulting in reduced Oand COexchange. Created with BioRender.com A B [47] [11] 2 2](https://europepmc.org/articles/PMC9491257/bin/12933_2022_1623_Fig3_HTML.jpg "Click to view full size")
A representation of our understanding of disease progression and pathophysiology from acute COVID-19 to long COVID.Depending on the severity of acute COVID-19 disease, dysregulation with increased levels of the following biomarkers have been found, namely P-selectin [], fibrinogen, D-dimer and VWF []. Abnormal clotting and hypercoagulability are seen early in acute COVID-19 disease with the development of thrombocytopaenia and a risk of bleeding as disease severity progresses. Therefore, the optimal time for intervention is early on in acute COVID-19 disease to address the presence of abnormal clotting.Progression to long COVID disease with patients presenting with debilitating symptoms such as "brainfog," dyspnoea, chest pain and chronic fatigue and the presence of microclots that may block capillaries with limited passage of red blood cells resulting in reduced Oand COexchange. Created with BioRender.com A B [47] [11] 2 2
Molecules regulating coagulation
The coagulation pathway to demonstrate the areas of action of the molecules involved in coagulation in our long COVID cohort compared to controls. Activation is illustrated by a line and arrow and inhibition by a line ending in a circular end. The Uniprot ID numbers of our molecules of interest were entered on the David Bioinformatics website and converted to an Entrez_Gene_ID gene list. The generated list was used to search the DAVID Bioinformatics website for molecular pathways where these molecules could potentially play a role. Here we demonstrate the coagulation cascade found on the KEGG pathway database.and. Diagram created with BioRender.com https://david.ncifcrf.gov/ https://www.genome.jp/kegg/pathway.html
Progression from acute COVID-19 tolong COVID and the persistence of microclots and a general hypoxic state, accompanied by increased circulating antibodies, proteins related to cellular function and liver protein dysfunction () A B C
Molecules regulating cellular function
Molecules that modulate cellular function that we found to be increased, included galectin-3-binding protein, Thrombospondin-1, Alpha-1-acid glycoprotein-2 as well as Inter-alpha-trypsin inhibitor heavy chain H1 and 2 (ITIH1 and ITIH2). Galectin-3 expression is known to be induced in viral infections and by a multitude of molecules that either mimic or are characteristic of ongoing inflammation and microbial infection, such as IFN-α, IFN-β, IFN-γ, TNF-α, poly(I:C), dsRNA, and dsDNA [64]. In addition, it is commonly overexpressed in most types of cancers [65] and is an important player in cancer development, progression, and metastasis via its interactions with galactoside-terminated glycans [66]. Furthermore, it interacts with the cell-surface glycoprotein CD146 (MCAM, MUC18) and induces secretion of metastasis-promoting cytokines from vascular endothelial cells [66]. Recently, it was also identified as a novel predictor of venous thromboembolism in systemic lupus erythematosus [67].
Thrombospondin-1 was also found to be increased in our cohort of long COVID participants. It is an adhesive glycoprotein that is released from platelet alpha-granules in response to thrombin stimulation and is also a transient component of the extracellular matrix in developing and repairing tissues [68]. Recently it was suggested that it might regulate haemostasis in vivo through modulation of platelet cAMP signalling at sites of vascular injury [69], and that it could mark a prothrombotic state and an underlying inflammatory process [70]. It is also increased in the tumour microenvironment [64] and might be involved in antiphospholipid syndrome [70], a condition well known to be associated with thrombosis.
Alpha-1-acid glycoprotein-2, which we also found to be elevated, is known to modulate the immune system during the acute-phase reaction. ITIH1 and ITIH2 were found to be elevated in our long COVID population. These molecules belong to the inter-α-trypsin inhibitors. Previously, it was reported that ITIH1 and ITIH2 were more abundant in a COVID-19 survivor group [71]. ITIH1 has previously been found to be elevated in patients with osteoarthritis [72]. ITIH1 is synthesized by chondrocytes and binds to hyaluronic acid and also to the extracellular matrix [73]. ITIH2 has been associated with demyelinating diseases [74].
We found decreased levels of a few molecules, namely Long palate, lung and nasal epithelium carcinoma-associated protein 1 (LPLC1_HUMAN,) Lactotransferrin, Adiponectin and Alpha-1-acid glycoprotein 1 (A1AG1_HUMAN) that might point to a type of immunosuppression. Our research group also suggested that Lactoferrin may be beneficial for preventing adverse effects of acute COVID-19, mainly due to its antiviral properties [75]. Previously, it was found that some critically ill COVID-19 patients could not be discharged from the ICU even though they exhibited negative viral tests [76]. Zhou and co-workers in 2021 suggested that in such patients, adaptive immunosuppression might be present, and ascribed it to a dysregulated host response to severe infection, similar to the immunosuppression that exists in patients with sepsis [76]. In long COVID, there has also been reports of immune suppression [54].
Of importance may be LPLC1, which may play an important role in innate immunity, as its function is related to binding of LPS, as a LPS-binding protein (https://www.uniprot.org/uniprot/C3TTP7↗). If LPS is not bound effectively, it may have significant implications for the response to LPS in circulation. This could possibly indicate an altered immune response to infectious pathogens. Related to LPS binding, is Lactotransferrin also known as lactoferrin (LF,) that was also decreased in our long COVID cohort. LF has important immunological properties and is both antibacterial and antiviral. In particular, there is evidence that it can bind to at least some of the receptors used by coronaviruses and thereby block their entry [75]. LF makes use of Heparan Sulfate Proteoglycans (HSPGs) on the surface of epithelial cells of the stomach to facilitate entry into the bloodstream via endocytosis [77, 78]. Coronaviruses bind to host cells by first attaching to HSPGs utilizing them as preliminary docking sites to assist with viral entry and LF is able to interfere with some of the receptors used by coronaviruses. LF can inhibit the entry of viral particles into host cells by blocking cellular receptors or via direct attachment to viral particles. In COVID-19 infection, LF might be able to competitively bind receptors as well as HSPGs and therefore prevent viral entry and the subsequent cytokine storm [75] but this still requires further investigation. Our finding of decreased levels of lactoferrin possibly indicates suppression of the host immune response in patients with long COVID.
Adiponectin has anti-inflammatory and anti-apoptotic properties that has shown to protect the vasculature, heart, lung, and colon [79], and was also reduced in our long COVID population. Pro-inflammatory and anti-inflammatory cytokines or adipokines namely adiponectin, leptin and resistin may be released from adipose tissue [80]. Adiponectin exists in two isoforms namely HMW (high molecular weight) and LMW (low molecular weight) adiponectin and is an important regulator of cytokine immune responses. These cytokine responses are isoform specific. IL-6 secretion by human monocytes and human monocytic leukemia cell line cells are stimulated by HMW adiponectin and does not inhibit LPS-induced IL-6 secretion. On the other hand, LMW adiponectin promotes IL-10 secretion and inhibits LPS-mediated IL-6 release. For example, in chronic hepatitis C infection these cytokines play an important role in the inflammatory and immune response of affected individuals. This could explain the different outcomes seen in hepatitis C infection. Some of the metabolic and inflammatory effects of adiponectin are regulated through the mitogen-activated protein kinase (MAPK) signalling pathway [80]. The MAPK pathway forms a crucial part in the regulation of IFN-α and INF-γ signalling in viral infections such as hepatitis C. The reduced level of adiponectin in our long COVID cohort also potentially points to an altered immune response in infected patients.
Alpha-1-acid glycoprotein 1 is an acute-phase protein [81] and functions as a transport protein in the blood stream, and it was found to be reduced in our long COVID participants. It is known to regulate inflammation, including binding of pathogens and modulating white blood cells' activity throughout the entire leukocyte attacking sequence [82]. This molecule is also known to modulate the immune system during the acute-phase reaction and decreased levels are related to the mortality of septic patients [83]. The decreased levels seen in the current cohort, might possibly indicate a dysregulated or abnormal immune or inflammatory response. It may therefore also be a predictor of morbidity and mortality in patients with COVID-19. If we look at the physiological processes that are regulated by the aforementioned molecules, the increased or reduced levels of these molecules will have an effect on cellular function and the potentially dysregulated immune response in these patients. They also have immune-related or cellular remodelling properties and may impact on vascular function.
Molecules regulating lipid metabolism and regulation
We also found interesting apolipoproteins, known to play a role in lipid metabolism and regulation. Apolipoprotein C-II (a component of very low density lipoproteins and chylomicrons) was found to be increased while Apolipoprotein A-II (the second most abundant protein of the high density lipoprotein particles) was reduced in our cohort. Previous studies support the crucial role that lipids and lipid metabolism play in SARS CoV-2 infection [84 –86]. Shen et al. performed proteomic and metabolomic profiling on the serum of 46 COVID-19 patients compared to 53 controls [84]. They found the downregulation of over 100 lipids, including sphingolipids, glycerophospholipids and fatty acids which correlated with disease severity in patients with COVID-19. Lipids, including sphingolipids and glycerophospholipids form an essential part of biomembranes. Specialized membrane domains exist in the plasma membrane and sphingolipids are an example of this. Sphingolipids are also involved in the regulation of signal transduction, immune activation pathways and inflammatory responses [87]. The downregulation of lipids in the sera of patients suffering from COVID-19 points to liver damage and changes in bilirubin and bile acids supports this. Song et al. studied the lipidome and metabolome of 50 patients with different severities (mild, moderate, and severe) of SARS CoV2 infection compared to 26 healthy controls by utilizing targeted and untargeted mass spectrometry of plasma samples that were collected [85]. They noted reductions of major classes of plasma glycerophospholipids, phosphatidic acids (PAs), phosphatidylinositols (PIs), and phosphatidylcholines (PCs) and increased concentrations of lysophospholipids namely lysophosphatidic acids (LPAs,) lysophosphatidylinositols (LPIs,) and lysophosphatidylcholines (LPCs.) Another finding was that the plasma lipidome of patients with COVID19 had similarities to monosialodihexosyl ganglioside (GM3)-enriched exosomes where levels of sphingomyelins (SMs) and GM3s are elevated, and diacylglycerols (DAGs) decreased. Increasing levels of GM3s were seen with progressive disease severity indicating that GM3-rich exosomes also play a role in the pathophysiology of COVID19.
From the literature it is evident that fluctuations in DGs (diglycerides,) FFAs (free fatty acids), and TGs (triglycerides) occur in pathological conditions. For example, increased lipolysis of adipose tissue is seen in Ebola virus disease where TGs are converted to FFAs and DGs, with increased recycling of fatty acids back into TGs [88, 89]. Bruzzone et al. found elevated levels of serum TG, TG-VLDL (VLDL, very low-density lipoproteins), TG-IDL (IDL, intermediate density lipoproteins), TG-LDL (LDL, low-density lipoproteins) and TG-HDL (HDL, high density lipoproteins) in patients with COVID-19 in contrast to a decreased total cholesterol (TC) concentration. They propose that serum accumulation of TG and TG-VLDL may indicate decreased oxidation of acetyl-CoA in the mitochondria of the liver. Ketone bodies are produced by the liver from fatty acid oxidation-derived acetyl-CoA [90]. This pathogenic redistribution of the lipoprotein particle size and composition increases the cardiovascular risk for patients with COVID-19 infection.
Literature supports the role that apolipoproteins and steroid hormones have to play in SARS CoV-2 infection. Shen and co-workers in 2020 [84] found decreased levels of apolipoproteins APOA1, APOA2, APOH, APOL1, APOD, and APOM in the serum of patients following SARS CoV2 infection. It has also previously been reported that APOA1 levels decreased when patients progressed from mild to severe disease [91]. These apolipoproteins are involved in the functioning of macrophages [92]. Arachidonic acid (AA) is an essential fatty acid. Prostaglandins, leukotrienes and thromboxanes are pro-inflammatory metabolites of AA and eicosapentaenoic acid (EPA). Lipoxins, resolvins, protectins and maresins are derivates of AA, EPA and docosahexaenoic acid (DHA) and are able to suppress the inflammatory response, enhance phagocytosis of macrophages as well as other immune cells and assist with microbial clearance [92, 93]. Therefore, lipids such as glycerophospholipids and fatty acids play a pivotal role in inflammation and the host immune response against viral infections.
In summary, lipid metabolism plays an integral role in COVID-19 disease, resulting in an imbalance between immune-regulating lipids, pro-inflammatory lipids and lipid mediators during the host immune response. It is evident that our findings of increased levels of Apolipoprotein C-II and reduced levels of Apolipoprotein A-II also supports this dysregulation of lipid metabolism in patients suffering from COVID-19 (see Fig. 5).
Immunoglobulins of interest
Table 3 shows selected immunoglobulins involved in the immune response and that might act as antibodies or autoantibodies. As can be noted in Table 3, there are numerous molecules with no data available on their function. However, we do list these molecules here, as it may be of value for immunologists to note the presence of these potentially important antibodies. Of specific interest was the presence of Immunoglobulin kappa chain V-III region POM (plasma membrane), that is known as rheumatoid factor (RF) and that may act as an autoantibody [33]. Another RF factor that was found to be elevated was Immunoglobulin kappa chain V-III region CLL.
Of significance also, was that there were numerous antibodies only present in 63 of our long COVID high responder samples and we present those in Table 4 that were present in 13% or more (arbitrary chosen cut-off) of the cohort. IG c1641_light_IGKV1-6_IGKJ4 (Fragment), IGL c3450_light_IGKV1-39_IGKJ1 (Fragment) and IGH c2558_heavy_IGHV3-20_IGHD2-2_IGHJ2 (Fragment) were found to be present in 27%, 24% and 22% of the 63 samples respectively. These antibodies were cross referenced on THE INTERNATIONAL IMMUNOGENETICS INFORMATION SYSTEM®'s IMGT/LIGM-DB database, but no data are available on these antibodies. These antibodies may have significance in the immune response following acute COVID-19 illness or driving auto-immunity in some long COVID participants.
Another important consideration is that patients with long-term persistent microclots, may also progress to develop auto-immune diseases. We suggest that this phenomenon might directly be due to autoantibodies that develop against antibodies or other molecules that are entrapped inside the fibrinaloid microclots. It appears that the long-term sequelae of many viral infections [94, 95], including long COVID [96, 97] may be attributed to autoimmunity. These microclots contain many different proteins that may present new epitopes if a conformational change has taken place. These epitopes may be recognized as 'non-self' eliciting an immune response with the possible development of autoantibodies. Additionally, oxidative stress induces the nitration of proteins leading to the production of autoantibodies. Autoantibodies formed against actin lead to muscle weakness [98]. In ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome), autoimmunity is well described [94]; and might also play an important role in long COVID because some autoantibodies share elements of epitope with the SARS-CoV-2 virus [99]. It has also been suggested that some of the viral sequences are amyloidogenic [100, 101]. Viral persistence may play a key role in patients suffering from long COVID [102], and therefore driving an ongoing immune response or the development of autoimmunity (see Fig. 5).
Pascolini et al. studied 33 consecutive patients with COVID-19 of whom 94% had interstitial pneumonia and compared them to 25 age- and sex-matched controls with fever and/or pneumonia of an etiology other than COVID-19 to evaluate for autoimmune serological markers [103]. 45% of patients with COVID-19 tested positive for at least one autoantibody and they found that 33% tested positive for antinuclear antibodies (ANAs), 24% tested positive for anti-cardiolipin antibodies (immunoglobulin (Ig)G and/or IgM) and 9% tested positive for anti-β2-glycoprotein antibodies (IgG and/or IgM.) Antineutrophil cytoplasmic antibodies (ANCA) were not present in any of their patients. A higher mortality rate was seen amongst patients with autoantibodies compared to those without.
Chang and coworkers searched for autoantibodies in hospitalized patients with COVID-19 and found that approximately 50% of hospitalized patients developed autoantibodies against one or more antigens in the array they tested for with 25% of patients being ANA positive [104]. They also discovered antibodies that are associated with relatively rare connective tissue diseases and have been predicted to be pathogenic. A large number of anti-cytokine antibodies (ACA) were identified as well as antibodies recognizing non-structural SARS-CoV-2 proteins which correlate with autoantibodies. A few of the antibodies they discovered include Anti-C1q, which is a SLE autoantigen, anti-β2GP1 (anti-beta 2 glycoprotein 1) a thrombogenic antibody, anti-BPI (anti-bactericidal permeability inducing protein) and anti-ACE2 antibodies.
Conversely, a study performed by Klein et al. suggest that autoantibodies have a limited role to play in the pathogenesis of long COVID [105]. Their findings point to the involvement of persistent viral antigen, reactivation of latent herpesviruses, and chronic inflammation in long COVID pathophysiology. There have been previous reports of persistent viral antigen in intestinal biopsies of patients recovering from COVID-19 infection and antigen persistence may therefore contribute to the host immune response in patients with long COVID [106, 107].
Conclusion
The present proteomics study provides further evidence of the importance of not only looking at the soluble inflammatory molecules present in blood samples of individuals who suffer from long COVID. Insoluble inflammatory molecules and immunoglobulins may be of significant importance in not only causing the persistent long COVID symptoms, but also eventually leading to these individuals developing auto-immune diseases. An important consideration is to resolve these microclots, address platelet hyperactivation and wide-spread vascular inflammation preferably in the acute phase of the disease. In that way auto-immunity and the resulting severe and debilitating symptoms due to these pathologies, might be prevented. In addition, if the microclots are resolved early in the disease, general hypoxia that may lead to irreversible tissue damage, could possibly be prevented. Such pathologies may have significant implications if patients already have co-morbidities such as type II diabetes or cardiovascular disease. There is therefore an urgent need for randomized controlled clinical trials to target the prevention or resolution of these microclots in circulation and reversal of the underlying associated endotheliopathy.